Estrella Immunopharma Inc (ESLA)
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers and solid tumors in the United States. Its lead candidate, EB103, is being evaluated in a Phase I/II clinical trial for diffuse large B-cell lymphoma. The company is also advancing EB104, a pre-clinical program for diffuse large B-cell lymphoma and acute lymphocytic leukemia, and EB201, a pre-clinical candidate being studied for systemic lupus erythematosus. Estrella’s ARTEMIS cell receptor platform is designed to support the development and commercialization of T-cell therapies targeting CD19 and CD22 for hematologic malignancies. The company has a collaborative agreement with Eureka and Imugene Limited related to solid tumor development using Imugene’s CF33-CD19t candidate together with EB103. Estrella Immunopharma was founded in 2006 and is headquartered in Emeryville, California. It is a subsidiary of Eureka Therapeutics, Inc.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ESLA
|
$0.80
|
-1.6% Downside
|
Fair
|
$12 1,381.5% Upside
|
—
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-2.6x
|
-6.6x
|
—
|
35.499 M
|
32.93 M
|
0.0%
|
32.8%
|
-26.8
|
—
|
60.5%
|
